Instead of a traditional chemotherapy comparison, Divarasib's registrational study is a head-to-head trial against approved KRAS G12C inhibitors. This trial design reflects a strategic shift towards proving superiority within a new drug class, not just efficacy against older standards of care.
With efficacy and toxicity profiles being nearly identical between the first approved KRAS G12C inhibitors, intracranial activity becomes a key differentiator for clinicians, especially since a third of these lung cancer patients develop brain metastases. Adagrasib's demonstrated CNS activity gives it a slight advantage.
Direxonrasib is showing unprecedented response rates (e.g., 47% in frontline) for metastatic pancreatic cancer, a historically difficult-to-treat disease. This high performance prompts comparisons to the targeted therapy successes seen in lung cancer, signaling a potential paradigm shift in treatment expectations for PDAC.
The KRAS G12D mutation, unlike the more common G12C, often occurs in younger, never-smoking lung cancer patients who previously lacked targeted therapy options. The high response rate (61%) and good tolerability of the G12D inhibitor Zoldanrasib could fill a significant unmet need in this specific demographic.
The confirmatory Code Break 200 study for sotorasib demonstrated a statistically significant improvement in progression-free survival (PFS) over docetaxel. However, it failed to show a similar benefit in overall survival (OS), a critical distinction for oncologists weighing long-term patient outcomes.
While the avutometanib/defactinib combination is newly approved for KRAS-mutated ovarian cancer, its significant toxicity profile—causing up to a third of patients to stop treatment—creates a clear clinical need for agents like specific KRAS inhibitors that may offer similar efficacy with better tolerability.